Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection

Drug Delivery

Volumn 22, Issue 5, 2015, Pages 627-637

  Li, Yanhong ^a   Su, Tingting ^a   Zhang, Yan ^a   Huang, Xingliang ^a   Li, Jing ^a   Li, Chong ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Antibiotics; Combination chemotherapy; Liposome; Severe infections

Indexed keywords

CLARITHROMYCIN; DAPTOMYCIN; LIPOSOME; MACROGOL; ANTIINFECTIVE AGENT; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG RELEASE; ELECTRON MICROSCOPY; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LIPOSOMAL DELIVERY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; DAPTOMYCIN; DISEASE MODELS, ANIMAL; LIPOSOMES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; POLYETHYLENE GLYCOLS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84937821756     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.880756     Document Type: Article

References (44)

1. Abdelghany SM, Quinn DJ, Ingram RJ, et al. (2012). Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomed 7:4053-63.
2. Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65: 36-48.
3. Anderson M, Omri A. (2004). The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv 11:33-9.
4. Canepari P, Boaretti M, Lleo MM, Satta G. (1990). Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 34:1220-6.
5. Chang S, Sievert DM, Hageman JC, et al. (2003). Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348:1342-7.
6. Cunha BA, Pherez FM. (2009). Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis 28:831-3.
7. Dailey CF, Pagano PJ, Buchanan LV, et al. (2003). Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47:2655-8.
8. Deresinski S. (2009). Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 49:1072-79.
9. Dong Y, Zhao X, Domagala J, Drlica K. (1999). Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43:1756-8.
10. Dopazo C, Bilbao I, Lazaro JL, et al. (2009). Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc 41:1021-4.
11. Drulis-Kawa Z, Dorotkiewicz-Jach A. (2010). Liposomes as delivery systems for antibiotics. Int J Pharm 387:187-98.
12. Fischer A, Yang SJ, Bayer AS, et al. (2011). Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 66:1696-711.
13. Fowler VG, Justice A, Moore C, et al. (2005). Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 40:695-703.
14. Fuchs PC, Barry AL, Brown SD. (2000). Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 38:51-8.
15. Garrod LP, Waterworth PM. (1962). Methods of testing combined antibiotic bactericidal action and the significance of the results. J Clin Pathol 15:328-38.
16. Goldrick B. (2002). First reported case of VRSA in the United States. Am J Nurs 102:17.
17. Hiramatsu K, Hanaki H, Ino T, et al. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-6.
18. Hoen B. (2002). Special issues in the management of infective endocarditis caused by gram-positive cocci. Infect Dis Clin North Am 16:437-52.
19. Hu CM, Aryal S, Zhang L. (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 1:323-34.
20. Jones RN, Barry AL. (1987). Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother 31:625-9.
21. Kazory A, Dibadj K, Weiner ID. (2006). Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 57:578-9.
22. Li C, Zhang X, Huang X, et al. (2013). Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomed 8:1285-92.
23. Liu X, Sun W, Zhang B, et al. (2013). Clarithromycin-loaded liposomes offering high drug loading and less irritation. Int J Pharm 443:318-27.
24. Mangili A, Bica I, Snydman DR, Hamer DH. (2005). Daptomycinresistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40:1058-60.
25. Metzler K, Hansen GM, Hedlin P, et al. (2004). Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24:161-7.
26. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, et al. (2011). Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 88:39-44.
27. Muppidi K, Wang J, Betageri G, Pumerantz AS. (2011). PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother 55:4537-42.
28. Nakajima Y. (1999). Mechanisms of bacterial resistance to macrolide antibiotics. J Infect Chemother 5:61-74.
29. Oleson FB, Berman CL, Kirkpatrick JB, et al. (2000). Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 44:2948-53.
30. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. (2010). Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54: 4329-34.
31. Pillai SK, Moellering RC, Eliopoulos GM. (2005). Antimicrobial combinations. In: Lorian V, ed. Antibiotics in laboratory medicine, 5th ed. Philadelphia, PA: The Lippincott Williams & Wilkins Co., 365-440.
32. Pumerantz A, Muppidi K, Agnihotri S, et al. (2011). Preparation of liposomal vancomycin and intracellular killing of meticillinresistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 37: 140-4.
33. Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. Faseb J 22:659-61.
34. Sande L, Sanchez M, Montes J, et al. (2012). Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model. J Antimicrob Chemother 67: 2191-4.
35. Shaffa M, Dayem S, Elshemy W. (2008). In vitro antibacterial activity of liposomal cephalexin against Staphylococcus aureus. Romanian J Biophys 18:293-300.
36. Silverman JA, Oliver N, Andrew T, Li T. (2001). Resistance studies with daptomycin. Antimicrob Agents Chemother 45:1799-802.
37. Skiest DJ. (2006). Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44:655-6.
38. Steenbergen JN, Alder J, Thorne GM, Tally FP. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283-8.
39. Straus SK, Hancock RE. (2006). Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with antimicrobial peptides and lipopeptides. Biochim Biophys Acta 9: 1215-23.
40. Veligandla SR, Louie KR, Malesker MA, Smith PW. (2004). Muscle pain associated with daptomycin. Ann Pharmacother 38:1860-2.
41. Voorn GP, Kuyvenhoven J, Goessens WH, et al. (1994). Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother 38:487-93.
42. Wayne. (2009). Clinical and Laboratory Standards Institute 2009: M07-A8-Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 18th ed. Pennsylvania, PA, 10 pp.
43. Wisplinghoff H, Bischoff T, Tallent SM, et al. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-17.
44. Zhao X, Drlica K. (2002). Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185:561-5.